Want to see IN:AJANTPHARM full AI Analyst Report?
AJANTPHARM Stock Chart & Stats
₹3366.45
₹16.60(0.49%)
At close: 4:00 PM EDT
₹3366.45
₹16.60(0.49%)
Day’s Range― - ―
52-Week Range₹2,335.00 - ₹3,598.40
Previous CloseN/A
Volume81.90K
Average Volume (3M)2.10K
Market Cap
₹433.54B
Enterprise Value₹346.33K
Total Cash (Recent Filing)₹6.65B
Total Debt (Recent Filing)₹2.60B
Price to Earnings (P/E)38.1
Beta0.40
Next Earnings
Nov 04, 2026EPS Estimate
24.05Next Dividend Ex-DateN/A
Dividend Yield0.81%
Share Statistics
EPS (TTM)84.53
Shares Outstanding124,935,620
10 Day Avg. Volume2,991
30 Day Avg. Volume2,099
Financial Highlights & Ratios
PEG Ratio2.23
Price to Book (P/B)7.74
Price to Sales (P/S)6.43
P/FCF Ratio231.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)98.72
Revenue Forecast (FY)₹62.67B
Bulls Say, Bears Say
Bulls Say
Conservative Balance Sheet / Low LeverageA very conservative balance sheet with low leverage provides lasting financial flexibility to invest in growth, withstand industry cycles, and support R&D or geographic expansion without immediate refinancing risk. This underpins durable capital allocation and reduces solvency risk over 2–6 months.
Consistent Revenue Growth And Strong MarginsSteady top-line growth combined with historically healthy net margins signals structural demand for branded generics and sustainable pricing power. Consistent revenue expansion and margin durability support predictable earnings and reinvestment capacity over the medium term.
Diversified Branded-generic Business ModelA dual domestic and international commercial model plus in-house manufacturing reduces single-market exposure and enables scale benefits. Diverse channels and product launches support resilient revenue streams and lower execution risk across markets over coming quarters.
Bears Say
Weakened Cash Conversion / Volatile Cash FlowMaterial deterioration in operating cash flow and free cash flow versus reported earnings implies working-capital swings or higher cash investments. Reduced cash predictability can limit discretionary spending, slow deleveraging or capex, and raise funding sensitivity over the medium term.
Margin Compression In FY2026A sharp gross-margin drop suggests persistent cost, mix, or pricing pressure that can erode operating leverage. If sustained, margin compression will reduce free cash generation and constrain reinvestment or margin-led earnings growth over the next several quarters.
Uptick In Debt Level To MonitorAn observable rise in debt, even from a low base, increases interest and refinancing exposure if cash conversion weakens. Continued reliance on incremental debt would materially reduce the balance sheet cushion and flexibility across a 2–6 month horizon if trends persist.
Ajanta Pharma Limited News
AJANTPHARM FAQ
What was Ajanta Pharma Limited’s price range in the past 12 months?
Ajanta Pharma Limited lowest stock price was ₹2335.00 and its highest was ₹3598.40 in the past 12 months.
What is Ajanta Pharma Limited’s market cap?
Ajanta Pharma Limited’s market cap is ₹433.54B.
When is Ajanta Pharma Limited’s upcoming earnings report date?
Ajanta Pharma Limited’s upcoming earnings report date is Nov 04, 2026 which is in 94 days.
How were Ajanta Pharma Limited’s earnings last quarter?
Ajanta Pharma Limited released its earnings results on Jul 30, 2026. The company reported ₹26.72 earnings per share for the quarter, beating the consensus estimate of ₹23.04 by ₹3.68.
Is Ajanta Pharma Limited overvalued?
According to Wall Street analysts Ajanta Pharma Limited’s price is currently Overvalued.
Does Ajanta Pharma Limited pay dividends?
Ajanta Pharma Limited pays a Annually dividend of ₹32 which represents an annual dividend yield of 0.81%. See more information on Ajanta Pharma Limited dividends here
What is Ajanta Pharma Limited’s EPS estimate?
Ajanta Pharma Limited’s EPS estimate is 24.05.
How many shares outstanding does Ajanta Pharma Limited have?
Ajanta Pharma Limited has 124,935,620 shares outstanding.
What happened to Ajanta Pharma Limited’s price movement after its last earnings report?
Ajanta Pharma Limited reported an EPS of ₹26.72 in its last earnings report, beating expectations of ₹23.04. Following the earnings report the stock price went up 0.935%.
Which hedge fund is a major shareholder of Ajanta Pharma Limited?
Currently, no hedge funds are holding shares in IN:AJANTPHARM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Ajanta Pharma Limited
Established in 1973 and headquartered in Mumbai, India, Ajanta Pharma Limited operates as a specialized pharmaceutical enterprise. This company, along with its subsidiaries, is dedicated to the development, manufacturing, and commercialization of finished dosage forms. Its extensive product range caters to numerous therapeutic categories, such as anti-infectives (antibiotic, anti-malarial), chronic disease management (anti-diabetic, cardiology), women's health (gynecology), pediatrics, respiratory ailments, general health, dermatology, ophthalmology, and pain management. Notable products include multivitamins, antibiotics, eye drops, and cough syrups. Ajanta Pharma boasts a substantial international footprint, operating across India, Africa, other parts of Asia, the United States, and additional global markets. Furthermore, it supplies its pharmaceutical offerings to various government entities, including armed forces, public hospitals, and governmental procurement departments.
Technical Analysis
Emcure Pharmaceuticals Limited
―
Glenmark Pharmaceuticals Limited
―
IPCA Laboratories Limited
―
―
Wockhardt Limited
―